蓝光柔性膀胱镜联合六氨基乙酰丙酸在膀胱癌监测中的疗效与安全性:III期对照多中心研究
本研究在高复发风险膀胱癌监测患者中比较蓝光与白光柔性膀胱镜。304例患者中103例转手术室,63例确诊恶性肿瘤,其中13例(20.6%,95%CI 11.5-32.7)仅蓝光发现复发(p<0.0001),5例为原位癌。蓝光镜在手术室还显著提高原位癌检出(9/26,34.6%,95%CI 17.2-55.7,p<0.0001),监测期间12例不良事件均非严重。
要点
- 蓝光柔性膀胱镜显著提高仅蓝光发现的复发患者比例(20.6%,p<0.0001)。
- 手术室蓝光镜显著提高仅蓝光发现的原位癌比例(34.6%,p<0.0001)。
- 监测期间12例不良事件均非严重,蓝光镜用于监测安全。
核心结论
- 诊室蓝光柔性膀胱镜显著提高复发膀胱癌患者的检出,用于监测安全。
- 手术室蓝光膀胱镜显著提高原位癌检出,并发现白光遗漏的病变。
研究设计与样本
- III期、对照、多中心研究,纳入高复发风险监测患者304例。
- 监测前膀胱内灌注六氨基乙酰丙酸,随机行蓝光柔性膀胱镜,可疑病变转手术室重复白光和蓝光膀胱镜并活检或切除,独立病理共识小组复核。
- 主要终点为仅蓝光柔性膀胱镜检出组织学确诊恶性肿瘤的患者比例。
主要发现
- 304例中103例转手术室,63例确诊恶性肿瘤,26例为原位癌。
- 63例中13例(20.6%,95%CI 11.5-32.7)复发仅蓝光柔性膀胱镜发现(p<0.0001),其中5例为原位癌。
- 手术室检查63例中26例(41%)确诊原位癌,其中9例(34.6%,95%CI 17.2-55.7)仅蓝光膀胱镜发现(p<0.0001)。
- 蓝光膀胱镜在63例中29例(46%)发现额外恶性病变。
- 白光和蓝光膀胱镜假阳性率均为9.1%;监测期间12例不良事件均非严重。
临床怎么用
- 诊室蓝光柔性膀胱镜可用于高复发风险膀胱癌监测,提高复发检出。
- 手术室蓝光膀胱镜可用于提高原位癌检出并发现白光遗漏病变。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We compared blue light flexible cystoscopy with white light flexible cystoscopy for the detection of bladder cancer during surveillance. MATERIALS AND METHODS: Patients at high risk for recurrence received hexaminolevulinate intravesically before white light flexible cystoscopy and randomization to blue light flexible cystoscopy. All suspicious lesions were documented. Patients with suspicious lesions were referred to the operating room for repeat white and blue light cystoscopy. All suspected lesions were biopsied or resected and specimens were examined by an independent pathology consensus panel. The primary study end point was the proportion of patients with histologically confirmed malignancy detected only with blue light flexible cystoscopy. Additional end points were the false-positive rate, carcinoma in situ detection and additional tumors detected only with blue light cystoscopy. RESULTS: Following surveillance 103 of the 304 patients were referred, including 63 with confirmed malignancy, of whom 26 had carcinoma in situ. In 13 of the 63 patients (20.6%, 95% CI 11.5-32.7) recurrence was seen only with blue light flexible cystoscopy (p <0.0001). Five of these cases were confirmed as carcinoma in situ. Operating room examination confirmed carcinoma in situ in 26 of 63 patients (41%), which was detected only with blue light cystoscopy in 9 of the 26 (34.6%, 95% CI 17.2-55.7, p <0.0001). Blue light cystoscopy identified additional malignant lesions in 29 of the 63 patients (46%). The false-positive rate was 9.1% for white and blue light cystoscopy. None of the 12 adverse events during surveillance were serious. CONCLUSIONS: Office based blue light flexible cystoscopy significantly improves the detection of patients with recurrent bladder cancer and it is safe when used for surveillance. Blue light cystoscopy in the operating room significantly improves the detection of carcinoma in situ and detects lesions that are missed with white light cystoscopy.
引用
- Daneshmand S, Patel S, Lotan Y, et al. Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study. J Urol. 2017. PMID: 29203268. doi:10.1016/j.juro.2017.11.096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。